Pharmaceutical markets in Central Asia have shown impressive growth in the first half of this year, according to Proxima Research. Kazakhstan and Uzbekistan, in particular, posted double-digit growth in monetary terms, highlighting their strong potential for continued expansion. 

📊 Key Market Trends:

• In Kazakhstan, the retail sales volume of pharmaceuticals and dietary supplements amounted to 371 billion KZT (+22% in monetary terms), while in Uzbekistan, it reached 12 trillion UZS (+22.2% in monetary terms).
• Both markets remain import-dependent: the share of imported drugs in Kazakhstan and Uzbekistan exceeds 80%.
• The average weighted cost per package of pharmaceuticals increased by 8% in Kazakhstan and nearly 30% in Uzbekistan, reflecting a shift in consumer preferences towards more expensive drugs.

🏢 Outlook and Conclusions: The pharmaceutical markets of Kazakhstan and Uzbekistan continue to grow, attracting the attention of investors and international companies. The governments of these countries are taking steps to reduce import dependence and stimulate the localization of production, which contributes to the creation of a more sustainable pharmaceutical market.

📌 Read the full material on our website to learn more about current trends, key players, and development opportunities in the pharmaceutical markets of Central Asia!

🔗 Full materials available here.

Proxima Research is the Analytical Partner of the Eurasian Pharmaceutical Summit 2024 that will be run by the Global Pharmaceutical Leaders’ Club in Tashkent and online on the 17th – 19th September. Join us to discuss the latest trends in the development of pharmaceutical markets in Central Asia, the Caucasus and Eastern Europe. Details about the summit are here: https://eurasianpharmasummit.com/en/